VVOS — Vivos Therapeutics Share Price
0.000.00%
Last trade - 00:00- $16.08m
- $9.82m
- $15.03m
- 10
- 38
- 25
- 13
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.02 | ||
| Price to Tang. Book | 3.39 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.07 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -108.39% | ||
| Return on Equity | -266.25% | ||
| Operating Margin | -74.32% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 13.07 | 16.89 | 16.02 | 13.8 | 15.03 | 17.3 | 20.91 | 5.7% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. The Company calls its solution The Vivos Method. The Vivos Method represents the first clinically effective non-invasive, non-surgical, non-pharmaceutical solution for treating mild to severe OSA. The Vivos Method includes treatment regimens that employ the proprietary Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and other modalities that alter the size, shape and position of the soft tissues that comprise a patient's upper airway and/or palate. It comprises various products and services, including Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, and Vivos Airway Intelligence Service, and others.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 12th, 2020
- Public Since
- December 11th, 2020
- No. of Shareholders
- 8,150
- No. of Employees
- 109
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 5,889,520
- Address
- 7921 Southpark Plaza,, Suite 210, LITTLETON, 80120
- Web
- https://vivos.com/
- Phone
- Contact
- Julie Gannon
- Auditors
- MOSS ADAMS LLP
Upcoming Events for VVOS
Q2 2025 Vivos Therapeutics Inc Earnings Release
Similar to VVOS
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the Vivos Therapeutics share price?
As of Today at 24:02 UTC, shares in Vivos Therapeutics are trading at $2.73. This share price information is delayed by 15 minutes.
How has the Vivos Therapeutics share price performed this year?
Shares in Vivos Therapeutics last closed at $2.73 and the price had moved by +3.8% over the past 365 days. In terms of relative price strength the Vivos Therapeutics share price has underperformed the S&P500 Index by -6.4% over the past year.
What are the analyst and broker recommendations for Vivos Therapeutics?
The overall consensus recommendation for Vivos Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Vivos Therapeutics dividend yield?
Vivos Therapeutics does not currently pay a dividend.
Does Vivos Therapeutics pay a dividend?
Vivos Therapeutics does not currently pay a dividend.
When does Vivos Therapeutics next pay dividends?
Vivos Therapeutics does not currently pay a dividend.
How do I buy Vivos Therapeutics shares?
To buy shares in Vivos Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vivos Therapeutics?
As of the previous close price of $2.73, shares in Vivos Therapeutics had a market capitalisation of $16.08m.
Where are Vivos Therapeutics shares listed?
Here are the trading details for Vivos Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: VVOS
What kind of share is Vivos Therapeutics?
Based on an overall assessment of its quality, value and momentum Vivos Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vivos Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Vivos Therapeutics is $5.85. That is 114.29% above the last closing price of $2.73.
Analysts covering Vivos Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.27 for the next financial year.
Find out moreWhat is the trend in the Vivos Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vivos Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +2.33%.
As of the last closing price of $2.73, shares in Vivos Therapeutics were trading -15.41% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vivos Therapeutics PE Ratio?
The Vivos Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.73.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vivos Therapeutics?
We do not have data on Vivos Therapeutics' directors